US-Made Drugs: Preferential Treatment in Medicare and Medicaid Programs.
This Act establishes a minimum 7-year demonstration program to prioritize drugs manufactured in the United States within federal health programs (Medicare, Medicaid, CHIP). For citizens, this could lead to lower out-of-pocket costs for certain medications and aims to strengthen the domestic supply chain for critical drugs, reducing reliance on foreign sources.
Key points
Lower Patient Costs: The program tests tools like reduced patient cost-sharing for US-manufactured drugs.
Supply Chain Security: Preference is given to companies that maintain high emergency reserves and diverse sourcing, mitigating the risk of drug shortages.
Domestic Manufacturing Support: Drugs must be made in the US by companies adhering to strict requirements regarding transparency and supply chain resilience.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.